DDInter927 DDInter1115
Inotuzumab ozogamicin is an antibody-drug conjugate using linker and cytotoxic drug technology similar to that developed for the ground-breaking treatment Mylotarg (), which was approved by the US FDA in 2000 for the treatment of acute myeloid leukaemia. Inotuzumab ozogamicin consists of a recombinant humanised IgG4 kappa CD22-targeting monoclonal antibody covalently attached to calicheamicin derivative, N-acetyl-gamma-calicheamicin dimethylhydrazide, which is a potent DNA-binding cytotoxic agent. Developed by Pfizer and UCB, inotuzumab ozogamicin was granted approval by EU in June 2017 followed by FDA on August 17th, 2017 for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). ALL is a rapidly progressing cancer of the bone marrow that is associated with
Magnesium citrate is a low volume and osmotic cathartic agent. The cathartic action works primarily through the high osmolarity of the solution which draws large amounts of fluid into space where is used. Magnesium citrate is considered by the FDA as an approved inactive ingredient for approved drug products under the specifications of oral administration of a maximum concentration of 237 mg. It is also considered as an active ingredient in over-the-counter products.
Magnesium citrate {u} may cause a minor interaction that can limit clinical effects when taken with {v} Linaclotide
Magnesium citrate {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Arsenic trioxide
Magnesium citrate {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Entrectinib
Magnesium citrate {u} may lead to a major life threatening interaction when taken with {v} Dolutegravir
Magnesium citrate {u} may lead to a major life threatening interaction when taken with {v} Bictegravir
Magnesium citrate may cause a minor interaction that can limit clinical effects when taken with Linaclotide
Magnesium citrate may cause a moderate interaction that could exacerbate diseases when taken with Arsenic trioxide
Magnesium citrate may cause a moderate interaction that could exacerbate diseases when taken with Entrectinib
Magnesium citrate may lead to a major life threatening interaction when taken with Dolutegravir
Magnesium citrate may lead to a major life threatening interaction when taken with Bictegravir